📬 GI Cancer Intelligence Digest — Week 2026-W32

FIND shows ctDNA methylation-guided surveillance doubles curative-intent salvage in resected colorectal cancer, COMMIT triggers a public re-evaluation of atezolizumab in MSI-H mCRC, TORCH reports TACE plus ablation median OS of 88.6 months in unresectable HCC, ARISTOTLE closes the door on irinotecan chemoradiotherapy, and CLARITY-Gastric01 delivers a positive OS readout for a CLDN18.2 ADC.

⚡ TL;DR

📄 Publications

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial. — Among 584 eligible patients (289 ctDNA-guided, 295 control) with median follow-up 23.3 months, recurrence rates were similar (18.0% v 18.6%, P = .919)
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. — PFS of FFX/bev/atezo was superior to atezo (HR 0.439 [95% CI, 0.23 to 0.84]; P = .0103)
Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial. — 36-month disease-free survival was 68% with irinotecan versus 67% with standard of care (HR 0.91 [95% CI 0.68-1.23]; p=0.54)
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial. — Median PFS was 17.7 months with TACE-ablation vs 7.3 months with TACE alone (HR 0.47; P < .001)

🐦 Twitter / 🦋 Bluesky

Real-world TriNetX comparison of atezolizumab/bevacizumab versus durvalumab/tremelimumab in first-line advanced HCC — In 1,530 propensity-score-matched pairs, overall survival was comparable (mOS 14.6 vs 17.3 months; aHR 0.96, p=0.62)
STELLAR 5-year update: short-course radiotherapy-based total neoadjuvant therapy holds an overall survival advantage without a disease-free survival difference — At 5 years, SCRT-based TNT improved overall survival (78.1% vs 69.7%; HR 0.74) with no significant disease-free survival difference
CLARITY-Gastric01: sonesitatug vedotin, an anti-CLDN18.2 ADC, meets its overall survival endpoint in second- and later-line gastric/GEJ cancer — AZD0901, an anti-CLDN18.2 ADC, improved OS versus second- or later-line chemotherapy in CLDN18.2+ gastric/GEJ cancer
Claudins as a druggable target class after CLDN18.2 approval, with a phase 3 LUCERNA design in CLDN18.2+, HER2-, PD-L1+ gastric cancer — The approval of CLDN18.2-targeted therapy validates claudins as actionable targets, with next-generation antibodies, ADCs, bispecifics and cell therapies in development
COMMIT published: positive trial reopens the question of whether atezolizumab belongs in MSI-H colorectal cancer at all — COMMIT reported HR 0.42 with median PFS 24.5 vs 5.3 months, ORR 86% vs 46%, and primary progression 2.8% vs 32.4% for FOLFOX/bevacizumab/atezolizumab versus atezolizumab alone

Full details below ↓

📄 What's Being Published

Manuscripts:

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial. — Mo Shaobo et al., J Clin Oncol

Among 584 eligible patients (289 ctDNA-guided, 295 control) with a median follow-up of 23.3 months, recurrence rates were similar (18.0% v 18.6%, P = .919), yet the ctDNA-guided group achieved a significantly higher rate of curative-intent treatment (48.1% v 23.6%, relative risk 2.03, P = .008). Median time to clinical recurrence was 9.5 v 13.4 months, representing a lead time of 3.9 months, and among recurrences confined to the liver and/or lungs, curative resection rates were 42.3% v 18.2% (P = .002).

Clinical bottom line: ctDNA methylation-guided surveillance converts more colorectal recurrences into resectable ones and should be tested against survival endpoints before it is adopted as routine follow-up.

Read full article →

🔗 Also discussed on social media →

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. — Rocha Lima Caio Max Sao Pedro et al., J Clin Oncol

From November 2017 to March 2025, 102 patients were enrolled across three arms (FFX/bev: n = 20, atezo: n = 41, FFX/bev/atezo: n = 41). PFS of FFX/bev/atezo was superior to atezolizumab alone (HR 0.439 [95% CI, 0.23 to 0.84]; P = .0103), with an objective response rate of 86.1% versus 46% and a 12-month disease control rate of 64.7% versus 32.4%.

Clinical bottom line: COMMIT is positive on paper but its real message is that single-agent atezolizumab underperforms other PD-1 agents in dMMR/MSI-H mCRC, which is why clinicians are now questioning atezolizumab's role rather than adding chemotherapy to immunotherapy.

Read full article →

🔗 Also discussed on social media →

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial. — Sebag-Montefiore David et al., Lancet Oncol

After exclusions, 564 patients were included in the modified intention-to-treat population (284 standard of care, 280 irinotecan). 36-month disease-free survival was 68% with irinotecan versus 67% with standard of care (HR 0.91 [95% CI 0.68–1.23]; p = 0.54), while grade 3 or worse events were substantially more frequent in the irinotecan arm (215 [78%] vs 148 [52%]).

Clinical bottom line: Irinotecan added to capecitabine chemoradiotherapy adds substantial toxicity with no disease-free survival gain and should not be used in locally advanced rectal cancer.

Read full article →

Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial. — Lyu Ning et al., JAMA Oncol

Median PFS was 17.7 months with TACE-ablation versus 7.3 months with TACE alone (HR 0.47; P < .001), and median OS was 88.6 months versus 35.1 months (HR 0.50; P < .001). Grade 3 and 4 treatment-related adverse events occurred in 23 patients (23.2%) in the TACE-ablation group and 24 (18.3%) in the TACE alone group.

Clinical bottom line: Sequential TACE followed by selective thermal ablation should be offered to BCLC stage B patients with low to moderate tumor burden, where it more than doubles progression-free survival without a meaningful toxicity penalty.

Read full article →

Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma. — Sun Xuqi et al., Clin Cancer Res

Across seven patients, the GPC3-targeted TCR fusion construct CT0180 produced an objective response rate of 28.6% and a disease control rate of 71.4%, with median progression-free and overall survival of 7.6 and 11.6 months, respectively. Cytokine release syndrome occurred in 85.7% of patients, all grade 1, with no dose-limiting toxicities observed.

Clinical bottom line: A GPC3-targeted TCR fusion construct produced responses with only grade 1 cytokine release syndrome in seven heavily pretreated HCC patients, an early safety signal that justifies dose expansion rather than any change in practice.

Read full article →

Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. — Tougeron David et al., J Immunother Cancer

Among 1,175 patients from 34 centers, 382 (32.5%) experienced an irAE, including 117 (10.0%) grade ≥3 events. Severe irAEs were associated with a better objective response rate (48.6% vs 34.6%, p < 0.0001), yet in a multivariable Cox model with irSAE as a time-dependent variable, no association with better PFS (HR = 1.280, p = 0.172) or OS (HR = 1.043, p = 0.828) was found; ICIs were resumed in 26.9% of patients after irSAE, with an irAE recurrence rate of 57.1%.

Clinical bottom line: A severe immune-related adverse event in dMMR/MSI-H digestive cancer carries a higher response rate but no survival advantage, so it must not be read as a favourable prognostic marker when deciding on rechallenge.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

Real-world TriNetX comparison of atezolizumab/bevacizumab versus durvalumab/tremelimumab in first-line advanced HCC

In 1,530 propensity-score-matched pairs, overall survival was comparable between atezolizumab/bevacizumab and durvalumab/tremelimumab (mOS 14.6 vs 17.3 months; aHR 0.96, p = 0.62), while treatment-requiring immune-related adverse events were significantly lower with atezolizumab/bevacizumab (20.2% vs 24.6%, aHR 0.61, p < 0.001). Separately, real-world treatment algorithms over ten years show less use of TACE and more SIRT and systemic therapy, though overall outcomes remain poor. The central question for clinicians is whether comparable survival between the two doublets means that the lower irAE burden with atezolizumab/bevacizumab should drive regimen selection.

Discussed by: @ronanhsieh, @ArndtVogel

→ View representative tweet

STELLAR 5-year update: short-course radiotherapy-based total neoadjuvant therapy holds an overall survival advantage without a disease-free survival difference

The 5-year STELLAR update shows that short-course radiotherapy-based total neoadjuvant therapy improved overall survival (78.1% vs 69.7%; HR 0.74) without a significant disease-free survival difference, with distant metastasis and locoregional recurrence also similar between arms. The OS benefit was most pronounced in high-risk patients, and outcomes after recurrence favored the TNT arm. Late watch-and-wait regrowth observed at 5–7 years is cited as a rationale for prolonged surveillance, while the dissociation between OS gain and DFS signal leaves clinicians debating whether short-course TNT should replace conventional chemoradiotherapy.

Discussed by: @ChandrakanthMv, @OncoAlert, @OncoAlert

→ View representative tweet

CLARITY-Gastric01: sonesitatug vedotin, an anti-CLDN18.2 ADC, meets its overall survival endpoint in second- and later-line gastric/GEJ cancer

The phase 3 CLARITY-Gastric01 trial reported that AZD0901 (sonesitatug vedotin), an anti-CLDN18.2 ADC, improved OS versus second- or later-line chemotherapy in CLDN18.2-positive gastric/GEJ cancer. In patients defined by a ≥25% CLDN18.2 threshold — a threshold that could include approximately 60% of patients — the OS benefit was significant in third-line and later and overall in second-line and later, while PFS improved numerically but not significantly, with no new safety signals identified. The trial met its primary OS endpoint in third- and later-line patients, with positive results across the broader population, and the agent was well tolerated. Clinicians are now considering how to sequence a CLDN18.2 ADC with OS benefit but non-significant PFS against zolbetuximab-based regimens in this population.

Discussed by: @OncoAlert, @OncoAlert, @OncoAlert, @TargetedOnc, @OncLive

→ View representative tweet

Claudins as a druggable target class after CLDN18.2 approval, with a phase 3 LUCERNA design in CLDN18.2+, HER2-, PD-L1+ gastric cancer

The approval of CLDN18.2-targeted therapy has validated claudins as actionable targets in epithelial cancers, with next-generation antibodies, ADCs, bispecifics, and cell therapies in development. The phase 3 LUCERNA trial of zolbetuximab plus pembrolizumab plus chemotherapy in CLDN18.2+, HER2-, PD-L1+ gastric/GEJ cancer has nearly completed enrollment. With multiple claudin-directed modalities now in trials, oncologists are debating how CLDN18.2 testing thresholds should be standardized across the gastroesophageal cancer setting.

Discussed by: @diegoadiazg, @CathyEngMD

→ View representative tweet

COMMIT published: positive trial reopens the question of whether atezolizumab belongs in MSI-H colorectal cancer at all

COMMIT reported an HR of 0.42 with median PFS of 24.5 vs 5.3 months, ORR 86% vs 46%, and primary progression 2.8% vs 32.4% for FOLFOX/bevacizumab/atezolizumab versus atezolizumab alone. Single-agent atezolizumab delivered 12-month PFS of 35% and 24-month PFS of 32%, compared with 12-month PFS of 55% and 24-month PFS of 48% for pembrolizumab in KEYNOTE-177. Clinicians are arguing that the trial calls into question atezolizumab as the immune checkpoint inhibitor of choice in this population, extending that concern to the adjuvant ATOMIC regimen.

Discussed by: @GIMedOnc, @GIMedOnc, @DrAllanPereira

→ View representative tweet

FIND phase III: ctDNA methylation-guided surveillance doubles curative-intent salvage after colorectal resection

The phase III FIND trial showed that ctDNA-guided surveillance produced a significantly higher rate of curative-intent treatment (48.1% v 23.6%, RR 2.03, P = 0.008), with recurrence detected 3.9 months earlier and curative resection of liver/lung recurrence achieved in 42.3% vs 18.2% of eligible patients. Commentators described this as a phase III RCT in which ctDNA methylation doubled curative-intent salvage after resection. The unresolved debate is whether that doubling is sufficient grounds to adopt ctDNA methylation surveillance before recurrence-free and overall survival endpoints have matured.

Discussed by: @jgong15, @OncoAlert, @DrAllanPereira

→ View representative tweet

🔥 Top Ranked Tweets

Vivek Subbiah, MD @VivekSubbiah

⭐️Delighted to see the Phase 3 trial of pemigatinib published in @JCO_ASCO !
👉Knew this drug would make it, right from the very first patient enrolled in the Phase 1 FIGHT-101 study published in @Annals_Oncology @myESMO 👉
Full circle moment🧬 @GIcancerDoc @chadinabhan @OncoAlert @oncodaily @OncBrothers
https://t.co/5MbmAYIsJ0
[Quoting @JCO_ASCO: Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial. Co-authored by @GIcancerdoc.

Read the full article. https://t.co/4Tm3YZ9hOx]

🔖 16 ❤️ 53 🔁 13 👁 8,941